Profiel
Inger Sandlie is the founder of Nykode Therapeutics ASA, founded in 2006, and Nextera AS, founded in 2009.
At Nextera AS, she held the title of Scientific Advisor.
Currently, Dr. Sandlie holds the position of Director at Radiumhospitalets Forskningsstiftelse and the title of Professor at the University of Oslo.
Actieve functies van Inger Sandlie
| Bedrijven | Functie | Begin |
|---|---|---|
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Invests in companies from Nordic research institutions | Directeur/Bestuurslid | - |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Eerdere bekende functies van Inger Sandlie
| Bedrijven | Functie | Einde |
|---|---|---|
| NYKODE THERAPEUTICS | Oprichter | - |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Invests in companies from Nordic research institutions | Finance |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nykode Therapeutics ASA
Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Commercial Services |
















